Ticker >

Rubra Medicaments share price

Checkpoint Trends Ltd.

BSE: 531099 SECTOR: Trading  3805   2   0

9.40
+0.02 (0.21%)
BSE: 12 Apr 04:01 PM

Price Summary

Today's High

₹ 9.57

Today's Low

₹ 8.97

52 Week High

₹ 12.39

52 Week Low

₹ 3.76

FinStar is Suspended!

FinStar can not be assigned to this company due to its dicey outlook and insufficient data. We will update the FinStar for this company as soon as the data is updated from its end.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

5.14 Cr.

Enterprise Value

5.26 Cr.

No. of Shares

0.55 Cr.

P/E

32.54

P/B

12.04

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  0.78

CASH

0.03 Cr.

DEBT

0.15 Cr.

Promoter Holding

0 %

EPS (TTM)

₹  0.29

Sales Growth

-42.31%

ROE

-38.44 %

ROCE

-13.1%

Profit Growth

-115.1 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-42.31%
3 Year5.51%
5 Year-12.78%

Profit Growth

1 Year-115.1%
3 Year-235.52%
5 Year8.73%

ROE%

1 Year-38.44%
3 Year-16.79%
5 Year-8.55%

ROCE %

1 Year-13.1%
3 Year-5.14%
5 Year-1.87%

Debt/Equity

0.8929

Price to Cash Flow

374.59

Interest Cover Ratio

-1215.73906485671

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 0 0
Dec 2023 0 0
Sep 2023 0 0
Jun 2023 0 0
Mar 2023 0 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 81.8382634122294 days.
  • Company has a healthy liquidity position with current ratio of 3.82855196935493.

 Limitations

  • The company has shown a poor profit growth of -235.522647946225% for the Past 3 years.
  • The company has shown a poor revenue growth of 5.51417021914655% for the Past 3 years.
  • Company has a poor ROE of -16.7888057843178% over the past 3 years.
  • Company has a poor ROCE of -5.14258457698064% over the past 3 years
  • Company has low Interest coverage ratio of -1215.73906485671.
  • The company has a low EBITDA margin of -6.95220316306635% over the past 5 years.
  • The company is trading at a high EV/EBITDA of 33.8017.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 0.21 0.08 0.2 0.29 0.17
Total Expenditure 0.21 0.19 0.25 0.03 0.11
Operating Profit 0 -0.11 -0.05 0.26 0.06
Other Income 0 0 0 0 0
Interest 0 0 0 0 0
Depreciation 0 0 0 0 0
Exceptional Items 0 0 0 0 0
Profit Before Tax 0 -0.11 -0.05 0.26 0.06
Tax 0 -0.01 0 0 0
Profit After Tax 0 -0.1 -0.05 0.26 0.06
Adjusted EPS (Rs) 0 -0.19 -0.1 0.47 0.1

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 0.59 0.99 0.49 2.01 1.16
Total Expenditure 0.77 0.97 0.48 2.03 1.24
Operating Profit -0.18 0.02 0.01 -0.02 -0.08
Other Income 0 0 0 0 0
Interest 0 0 0 0 0
Depreciation 0 0 0 0 0
Exceptional Items 0.17 0.03 0 0 0
Profit Before Tax -0.01 0.05 0.01 -0.02 -0.08
Tax 0 0.01 0 0.01 0
Net Profit -0.01 0.03 0.01 -0.04 -0.08
Adjusted EPS (Rs.) -0.02 0.06 0.01 -0.07 -0.14

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 5.47 5.47 5.47 5.47 5.47
Total Reserves -4.89 -4.86 -4.85 -4.89 -4.97
Borrowings 0 0 0 0 0
Other N/C liabilities 0 0 0 0 0
Current liabilities 0.12 0.14 0.29 0.27 0.16
Total Liabilities 0.7 0.75 0.9 0.85 0.66
Assets
Net Block 0.02 0.02 0.01 0.01 0.06
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 0 0 0 0 0
Other N/C Assets 0 0 0 0 0
Current Assets 0.68 0.74 0.89 0.83 0.6
Total Assets 0.7 0.75 0.9 0.85 0.66
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations -0.18 0.02 0.01 -0.02 -0.08
Adjustment 0 0 0 0 0
Changes in Assets & Liabilities -0.01 0.08 0.51 -0.47 0.09
Tax Paid 0 -0.01 0 -0.01 0
Operating Cash Flow -0.03 0.12 0.52 -0.5 0.01
Investing Cash Flow 0 0 0 0 0
Financing Cash Flow -0.17 -0.26 0 0 0
Net Cash Flow -0.2 -0.14 0.52 -0.5 0.01

Corporate Actions

Investors Details

 No Promoters Data available for this company.
Report us
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 100.00 100.00 100.00 100.00 100.00
aditya baid 2.93 2.93 2.93 2.92 2.93
aman baid 1.83 1.83 1.83 1.83 1.83
atul panday 2.15 2.15 2.15 2.15 2.15
divya gupta 2.74 2.74 2.74 2.74 2.50
gatraj jain 3.66 3.66 3.66 3.66 3.66
ghanshyam chunilal chuda... 1.48 1.48 1.48 1.48 1.48
kartik sunil jain 5.04 5.04 5.04 5.04 5.04
meena baid 2.74 2.74 2.74 2.74 2.74
pooja panday 1.33 1.33 1.33 1.33 1.33
rakesh baid 3.66 3.66 3.66 3.66 3.66
religare finvest ltd 5.89 5.89 5.89 5.89 5.89
sanjaykumar sarawagi 1.43 1.43 1.43 1.43 1.43
tara devi toshniwal 16.31 16.31 16.31 16.30 16.31
vijay v doshi 1.31 1.31 1.31 1.31 1.31

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Checkpoint Trends informs about newspapers advertisement 12 Feb 2024, 1:25PM Rubra Medicaments - Quaterly Results7 Feb 2024, 3:45PM Rubra Medicaments - Quaterly Results7 Feb 2024, 3:45PM Rubra Medicaments - Quaterly Results7 Feb 2024, 3:45PM Rubra Medicaments - Quaterly Results7 Nov 2023, 2:38PM Rubra Medicaments - Quaterly Results7 Nov 2023, 2:38PM Checkpoint Trends submits intimation for notice of board meeting28 Oct 2023, 12:16PM Checkpoint Trends informs about newspaper publication 17 Aug 2023, 5:02PM Checkpoint Trends informs about board meeting 2 Aug 2023, 5:07PM Rubra Medicaments informs about trading window closure28 Dec 2022, 3:16PM Checkpoint Trends informs about outcome of board meeting 14 Nov 2022, 2:05PM Rubra Medicaments - Quaterly Results10 Nov 2022, 3:37PM Rubra Medicaments - Quaterly Results10 Nov 2022, 3:37PM Checkpoint Trends informs about board meeting 28 Oct 2022, 10:42AM Rubra Medicaments informs about annual report3 Sep 2022, 12:49PM Rubra Medicaments informs about board meeting1 Aug 2022, 5:00PM Rubra Medicaments informs about certificate 2 Jun 2022, 11:51AM Checkpoint Trends informs about newspaper publication 28 May 2022, 11:40AM Rubra Medicaments - Quaterly Results25 May 2022, 4:37PM Rubra Medicaments - Quaterly Results25 May 2022, 4:37PM Rubra Medicaments informs about certificate11 Apr 2022, 4:32PM Rubra Medicaments informs about press release9 Mar 2022, 5:21PM Rubra Medicaments informs about board meeting24 Feb 2022, 2:40PM Rubra Medicaments informs about closure of trading window3 Jan 2022, 12:41PM Rubra Medicaments informs about newspaper publication16 Nov 2021, 10:06AM Rubra Medicaments informs about board meeting2 Aug 2021, 10:52AM Rubra Medicaments informs about appointment of director15 Apr 2021, 3:23PM Rubra Medicaments informs about certificate16 Oct 2020, 10:45AM Rubra Medicaments informs about appointment of CS cum CO24 Sep 2020, 1:18PM

Rubra Medicaments Stock Price Analysis and Quick Research Report. Is Rubra Medicaments an attractive stock to invest in?

 

Stock investing requires careful analysis of financial data to find out the company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement. This can be time-consuming and cumbersome. An easier way to find out about a company's performance is to look at its financial ratios, which can help to make sense of the overwhelming amount of information that can be found in a company's financial statements.

Here are the few indispensable tools that should be a part of every investor’s research process.

  • PE ratio: - Price to Earnings' ratio, which indicates for every rupee of earnings how much an investor is willing to pay for a share. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Rubra Medicaments has a PE ratio of 32.5372101073036 which is high and comparatively overvalued .

  • Share Price: - The current share price of Rubra Medicaments is Rs 9.4. One can use valuation calculators of ticker to know if Rubra Medicaments share price is undervalued or overvalued.

  • Return on Assets (ROA): - Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Rubra Medicaments has ROA of -10.4298210975273 % which is a bad sign for future performance. (higher values are always desirable)

  • Current ratio: - The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Rubra Medicaments has a Current ratio of 3.82855196935493 .

  • Return on equity: - ROE measures the ability of a firm to generate profits from its shareholders investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Rubra Medicaments has a ROE of -38.4442168104497 % .(higher is better)

  • Debt to equity ratio: - It is a good metric to check out the capital structure along with its performance. Rubra Medicaments has a D/E ratio of 0.8929 which means that the company has low proportion of debt in its capital.

  • Inventory turnover ratio: - Inventory Turnover ratio is an activity ratio and is a tool to evaluate the liquidity of a company's inventory. It measures how many times a company has sold and replaced its inventory during a certain period of time. Rubra Medicaments has an Inventory turnover ratio of 0 which shows that the management is inefficient in relation to its Inventory and working capital management.

  • Sales growth: - Rubra Medicaments has reported revenue growth of -42.3129515541169 % which is poor in relation to its growth and performance.

  • Operating Margin: - This will tell you about the operational efficiency of the company. The operating margin of Rubra Medicaments for the current financial year is -6.83795198896694 %.

  • Dividend Yield: - It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Rubra Medicaments is Rs 0 and the yield is 0 %.

Last Updated on:
Brief about Rubra Medicaments
X